Search results for "DNA vaccination"

showing 10 items of 22 documents

Preproinsulin designer antigens excluded from endoplasmic reticulum suppressed diabetes development in nod mice by dna vaccination

2019

DNA vaccines against autoimmune type 1 diabetes (T1D) contain a nonpredictable risk to induce autoreactive T cell responses rather than a protective immunity. Little is known if (and how) antigen expression and processing requirements favor the induction of autoreactive or protective immune responses by DNA immunization. Here, we analyzed whether structural properties of preproinsulin (ppins) variants and/or subcellular targeting of ppins designer antigens influence the priming of effector CD8+ T cell responses by DNA immunization. Primarily, we used H-2b RIP-B7.1 tg mice, expressing the co-stimulator molecule B7.1 in beta cells, to identify antigens that induce or fail to induce autoreacti…

0301 basic medicinepreproinsulin/proinsulin antigensPreproinsulinlcsh:QH426-470type 1 diabetesMouse ModelsBiologyMajor histocompatibility complexArticleDNA vaccinationDNA vaccines03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunityGeneticsmouse models:Science::Medicine [DRNTU]lcsh:QH573-671Molecular BiologyNOD micelcsh:Cytologylcsh:Geneticsendoplasmic reticulum030104 developmental biology030220 oncology & carcinogenesisImmunologybiology.proteinType 1 DiabetesMolecular MedicineCD8
researchProduct

Recent advances in the use of nanoparticles for allergen-specific immunotherapy

2017

The number of patients suffering from allergic asthma and rhinoconjunctivitis has increased dramatically within the last decades. Allergen-specific immunotherapy (AIT) is the only available cause-oriented therapy so far. AIT reduces symptoms, but has also a disease-modifying effect. Disadvantages are a long-lasting procedure, and in a few cases potential systemic adverse reactions. Encapsulation of allergens or DNA vaccines into nanostructures may provide advantages compared to the conventional AIT with noncapsulated allergen extracts: The protein/DNA molecule can be protected from degradation, higher local concentrations and targeted delivery to the site of action appear possible, and most…

0301 basic medicinemedicine.medical_treatmentImmunologyBiocompatible Materials02 engineering and technologymedicine.disease_causeImmunoglobulin EDNA vaccination03 medical and health sciencesAllergenImmune systemHypersensitivitymedicineAnimalsHumansImmunology and AllergyDrug Carriersbiologybusiness.industryImmunotherapyAllergens021001 nanoscience & nanotechnologyNanomedicine030104 developmental biologyDesensitization ImmunologicLiposomesDrug deliveryImmunologybiology.proteinNanoparticlesNanomedicine0210 nano-technologybusinessDrug carrierAllergy
researchProduct

Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin.

2003

Strong cell-type-specific promoters are basic tools in gene therapy allowing for novel applications and focused strategies by transcriptionally targeting gene expression to selected cells. In immunotherapy, dendritic cells (DC) are of central importance, since they represent the principal inducers of immune responses. Here we describe isolation and use of the promoter of the murine actin-bundling protein fascin to target transcriptionally gene expression to cutaneous DC. Using the reporter gene enhanced green fluorescent protein (EGFP), we demonstrate that the fascin promoter mediates a strong antigen expression that is restricted to mature DC. DNA vaccination with antigen-encoding expressi…

Transcription GeneticBiologyCD8-Positive T-LymphocytesDNA vaccinationMiceGenes ReporterGene expressionGeneticsVaccines DNAAnimalsPromoter Regions GeneticMolecular BiologyFascinReporter geneMice Inbred BALB CExpression vectorMicrofilament ProteinsPromoterDendritic cellTransfectionDendritic CellsGenetic TherapyBiolisticsMolecular biologyMice Inbred C57BLbiology.proteinMolecular MedicineCarrier ProteinsGene therapy
researchProduct

Vaccination with ENO1 DNA Prolongs Survival of Genetically Engineered Mice with Pancreatic Cancer

2013

Background & Aims Pancreatic ductal adenocarcinoma (PDA) is an aggressive tumor, and patients typically present with late-stage disease; rates of 5-year survival after pancreaticoduodenectomy are low. Antibodies against α-enolase (ENO1), a glycolytic enzyme, are detected in more than 60% of patients with PDA, and ENO1-specific T cells inhibit the growth of human pancreatic xenograft tumors in mice. We investigated whether an ENO1 DNA vaccine elicits antitumor immune responses and prolongs survival of mice that spontaneously develop autochthonous, lethal pancreatic carcinomas. Methods We injected and electroporated a plasmid encoding ENO1 (or a control plasmid) into Kras G12D /Cre (KC) mice …

medicine.medical_treatmentDNA Vaccine; Enolase; Parnceratic cancer; Transgeneic miceEnolasegenetically engineered miceceEnzyme-Linked Immunosorbent AssayTransgeneic miceDNA vaccination03 medical and health sciencesMice0302 clinical medicineImmune systemPancreatic cancerGenetic modelmedicineVaccines DNADNA VaccineAnimalsSurvival rate030304 developmental biology0303 health sciencesImmunity CellularHepatologybiologyENO.1; DNA Vaccine; genetically engineered miceceVaccinationGastroenterologyParnceratic cancerImmunotherapyNeoplasms Experimentalmedicine.diseaseImmunohistochemistryMice Mutant Strains3. Good healthPancreatic NeoplasmsSurvival RateSettore BIO/18 - GeneticaTumor progression030220 oncology & carcinogenesisPhosphopyruvate HydrataseImmunologybiology.proteinAntibodyENO.1Carcinoma Pancreatic Ductal
researchProduct

Efficiency of Biolistic DNA Vaccination in Experimental Type I Allergy

2012

Gene gun-mediated delivery of allergen-encoding plasmid DNA has been in focus for many years now as being a needle-free alternative to the protein-based desensitization regimen used in specific immunotherapy. Biolistic immunization with the Helios gene gun has proven to be potent in the induction of antigen-specific CD4(+) and CD8(+) T cells. Here we describe biolistic vaccination in experimental mouse models of IgE-mediated type I allergy as well as allergen-induced airway inflammation.

Vaccinationbusiness.industrymedicine.medical_treatmentImmunologyAirway inflammationType i allergyMedicinebusinessGeneCD8Gene gunDNA vaccinationDesensitization (medicine)
researchProduct

Influenza control in the 21st century: Optimizing protection of older adults

2009

Older adults (> or =65 years of age) are particularly vulnerable to influenza illness. This is due to a waning immune system that reduces their ability to respond to infection, which leads to more severe cases of disease. The majority ( approximately 90%) of influenza-related deaths occur in older adults and, in addition, catastrophic disability resulting from influenza-related hospitalization represents a significant burden in this vulnerable population. Current influenza vaccines provide benefits for older adults against influenza; however, vaccine effectiveness is lower than in younger adults. In addition, antigenic drift is also a concern, as it can impact on vaccine effectiveness due t…

DiseaseVaccines AttenuatedAntigenic driftDNA vaccinationAdjuvants ImmunologicCost of IllnessImmunityInfluenza HumanHumansMedicineAntigens ViralAgedAttenuated vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryHealth PolicyImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaccines VirosomeVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicinebusinessVaccine
researchProduct

The immunodominant CD8 T cell response to the human cytomegalovirus tegument phosphoprotein pp65(495-503) epitope critically depends on CD4 T cell he…

2011

Abstract Immunodominance hierarchies operating in immune responses to viral Ags limit the diversity of the elicited CD8 T cell responses. We evaluated in I-Ab+/A2-HHD-II and HLA-DR1+/A2-DR1 mice the HLA-A*0201–restricted, multispecific CD8 T cell responses to the human CMV tegument phosphoprotein pp65 (pp65) Ag. Vaccination of mice with pp65-encoding DNA elicited high IFN-γ+ CD8 T cell frequencies to the pp65495–503/(e6) epitope and low responses to the pp65320–328/(e3) and pp65522–530/(e8) epitopes. Abrogation of the e6-specific immunity efficiently enhanced e3- and e8-specific T cell responses by a pp65Δ501–503 DNA vaccine. The immunodominant e6-specific (but not the e3- and e8-specific) …

CD4-Positive T-LymphocytesvirusesT cellImmunologyEpitopes T-LymphocyteMice TransgenicImmunodominanceBiologyCD8-Positive T-LymphocytesLymphocyte ActivationTransfectionEpitopeDNA vaccinationViral Matrix ProteinsMiceImmune systemHLA-A2 AntigenmedicineImmunology and AllergyCytotoxic T cellAnimalsHumansAntigen-presenting cellHLA-A AntigensImmunodominant EpitopesVaccinationvirus diseasesPhosphoproteinsVirologyMolecular biologymedicine.anatomical_structureHEK293 CellsPhosphoproteinJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Hepatitis B- a Therapeutic Vaccine: Hope or Hype?

2010

business.industryHepatitis Bmedicine.diseaseVirologyVaccine therapyDNA vaccinationClinical trialVaccinationImmunizationImmunologyMedicineTherapeutic vaccinebusinessViral hepatitis
researchProduct

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

2015

Abstract Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin. Experimental Design: Twenty-seven patients with CEA-expressing carcinomas were recruited: 15 patients with measurable disease (arm-I) and 12 patients without radiological evidence of disease (arm-II). Six intramuscular vaccinations of naked DNA (1 mg/dose) were administered up to week 12. Clinical and immunologic follow-up was up to week 64 or clinical/radiological disease. Results: DOM-specific immune responses demonstrated successful vaccine delivery. All p…

Cytotoxicity ImmunologicMaleCancer ResearchCD8-Positive T-LymphocytesLymphocyte ActivationCancer VaccinesArticleDNA vaccination03 medical and health sciences0302 clinical medicineCarcinoembryonic antigenImmune systemVaccines DNAMedicineHumansAdverse effectbiologybusiness.industryCarcinomaCancermedicine.diseaseCarcinoembryonic AntigenVaccinationOncologyNaked DNA030220 oncology & carcinogenesisImmunologybiology.proteinFemaleAntibodybusinessOligopeptides030215 immunology
researchProduct

Strategies in DNA vaccine for melanoma cancer

2020

According to reports of the international agency for cancer on research, although malignant melanoma shows less prevalence than nonmelanoma skin cancers, it is the major cause of skin cancer mortality. Given that, the production of effective vaccines to control melanoma is eminently required. In this regard, DNA-based vaccines have been extensively investigated for melanoma therapy. DNA vaccines are capable of inducing both cellular and humoral branches of immune responses. These vaccines possess some valuable advantages such as lack of severe side effects and high stability compared to conventional vaccination methods. The ongoing studies are focused on novel strategies in the development …

0301 basic medicineSkin NeoplasmsDermatologyCancer VaccinesGeneral Biochemistry Genetics and Molecular BiologyDNA vaccination03 medical and health sciences0302 clinical medicineImmune systemVaccines DNAmedicineHumansMelanomaMelanoma-associated antigenbusiness.industryMelanomaCancermedicine.diseaseVaccinationClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologySkin cancerbusinessPigment Cell & Melanoma Research
researchProduct